Program subject to change.
9:00 - 9:15 | Opening Welcome Remarks (Great Hall) | ||||||
Welcome Remarks EACPT2025 Chair Janne Backman, University of Helsinki, Helsinki, Finland, and EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands | ||||||
9:20 - 10:00 | Keynote Lecture 1 (Great Hall) | ||||||
Chair: Janne Backman, University of Helsinki, Helsinki, Finland The role of the European Medicines Agency in advancing science and innovation in Europe Steffen Thirstrup, Chief Medical Officer, European Medicines Agency | ||||||
10:00 - 10:30 | Refreshment Break (Catering areas on 1st and 2nd floor) |
10:30 - 12:00 | Concurrent Sessions | |||||||||||
Awards session (EPHAR/EACPT) (Great Hall) Co-Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands, EPHAR Chairperson Maria Jesus Sanz, University of Valencia, Valencia, Spain, and FSCP Chair Mikko Niemi, University of Helsinki, Helsinki, Finland In this session, we will announce the recipients of the Joint EPHAR‐EACPT Young Investigator Awards in Pharmacology 2025, followed by presentations from the awardees. Additionally, the Finnish Society of Clinical Pharmacology will present its awards and recognitions, including a presentation by the Best PhD Thesis 2024 awardee. | |||||||||||
10:30 - 11:00 | Joint EPHAR‐EACPT Young Investigator Award in Pharmacology 2025; EPHAR Award presentation | ||||||||||
11:00 - 11:30 | Joint EPHAR‐EACPT Young Investigator Award in Pharmacology 2025; EACPT Award presentation | ||||||||||
11:30 - 12:00 | Finnish Society of Clinical Pharmacology (FSCP) Awards and recognitions | ||||||||||
Session B1: Preclinical data informing clinical pharmacology (Small Hall) Chairs: Mikko Koskinen, Orion Corporation, Espoo, Finland and Piet van der Graaf, Certara, Canterbury, United Kingdom | |||||||||||
10:30 - 11:00 | QSP modelling - Speeding dose escalation trials in immuno-oncology Piet van der Graaf, Certara, Canterbury, United Kingdom | ||||||||||
11:00 - 11:30 | Translational PKPD informing clinical dose selection Pablo Morentin Gutierrez, AstraZeneca, Cambridge, United Kingdom | ||||||||||
11:30 - 11:45 | Identifying Parkinson's disease-associated genes via a genome-wide association study of Taiwanese population and a cell model (Abstract O001) Ping Lin Tsai, National Cheng Kung University, Tainan, Taiwan | ||||||||||
11:45 - 12:00 | In vivo assessment of MRP1 activity in murine and human skeletal muscle (Abstract O002) Matthias Jackwerth, Medical University of Vienna, Vienna, Austria | ||||||||||
Session C1: Therapeutic advances in the treatment of obesity (Auditorium) Chairs: Eriika Savontaus, University of Turku, Turku, Finland and Dominique Deplanque, University of Lille, Lille, France | |||||||||||
10:30 - 11:00 | Next generation anti-obesity drugs Christoffer Clemmensen, University of Copenhagen, Copenhagen, Denmark | ||||||||||
11:00 - 11:30 | Pharmacovigilance of anti-obesity drugs Jean-Luc Faillie, CHU de Montpellier, Montpellier, France | ||||||||||
11:30 - 11:45 | Lingonberry supplementation induces anti-obesity and health-promoting effects on gut microbiome in high-fat diet-induced experimental obesity (Abstract O003) Iiro Piippo, Tampere University, Tampere, Finland | ||||||||||
11:45 - 12:00 | Effect of methylphenidate on BMI in children in relation to weight status (Abstract O004) Jenny Kindblom, Sahlgrenska University Hospital, Gothenburg, Sweden | ||||||||||
12:00 - 14:00 | Lunch and Poster ViewingLunch (Catering areas in 1st and 2nd floor) |
12:30 - 14:00 | Trainee poster award nominees (posters A101-A120) | ||||||||||||||
12:30 - 13:15 Nominee presentations to Awards Committee 13:15 - 14:00 Presenters at posters | |||||||||||||||
13:00 - 14:00 | Presenters at posters P201-P220, P301-P324, P401-413 |
14:00 - 15:30 | Concurrent Sessions | |||||
Session A1: Multiprofessional approach to pharmacotherapy (Auditorium) Chairs: Lasse Lehtonen, Helsinki University Hospital, Helsinki, Finland and Raisa Laaksonen, University of Helsinki, Helsinki, Finland | |||||
14:00 - 14:30 | Importance of clinical pharmacological and pharmaceutical care for medication safety with oral antitumor therapy Martin Fromm, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany | ||||
14:30 - 15:00 | Minimizing the risks in pharmacotherapy with medication review Eva Sædder, Aarhus University Hospital, Denmark | ||||
15:00 - 15:15 | The tailored youngAMBORA care program during pediatric oral antitumor therapy solves medication errors and improves satisfaction with information (Abstract O005) Phyllis Lensker, Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany | ||||
15:15 - 15:30 | Drug-related problems from the pharmaceutical care perspective and the healthcare perspective: an explorative analysis (Abstract O006) Per Thysell, Sahlgrenska University Hospital, Gothenburg, Sweden | ||||
Session B2: Artificial intelligence in drug development (Great Hall) Chairs: Sammeli Liikkanen, Orion Corporation, Turku, Finland and Lauren Walker, University of Liverpool, Liverpool, United Kingdom | |||||
14:00 - 14:30 | Use of AI in the medication safety field Lauren Walker, University of Liverpool, Liverpool, United Kingdom | ||||
14:30 - 15:00 | AI to reveal hidden biological mechanisms of disease and discover breakthrough drugs by digital twins Bruce Church, Aitia, Cambridge, Massachusetts, United States | ||||
15:00 - 15:15 | Drug-induced changes in gastrointestinal pacemaker activity may predict drug adverse reactions beyond the gut using a deep learning approach (Abstract O007) Yuen Hang LIU, The Chinese University of Hong Kong, Hong Kong, Hong Kong | ||||
15:15 - 15:30 | How well can current decision support systems predict adverse drug events and can predicts be improved using machine learning? (Abstract O008) Marine L. Andersson, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden | ||||
Session C2: Immunopharmacology (Small Hall) Chairs: Eeva Moilanen, Tampere University, Tampere, Finland and Ulf Simonsen, Aarhus University, Aarhus, Denmark | |||||
14:00 - 14:30 | Glucocorticoids: Novel insights into mechanisms Karolien De Bosscher, UGent Department of Biomolecular Medicine, Ghent, Belgium | ||||
14:30 - 15:00 | Transient Receptor Potential (TRP) ion channels: Novel TRPA1 inhibitor for chronic pain. Preclinical and phase I clinical results Zsuzsanna Helyes, Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary | ||||
15:00 - 15:15 | Effect of severe renal function impairment on the single-dose pharmacokinetics, pharmacodynamics, safety, and tolerability of cenerimod (Abstract O009) Markus Stefan Mueller, Viatris Innovation GmbH, Allschwil, Switzerland | ||||
15:15 - 15:30 | The contact allergen methylisothiazolinone (MIT) is a potent activator of the TRPA1 ion channel (Abstract O010) Ilari Mäki-Opas, Tampere University, Tampere, Finland | ||||
15:30 - 16:00 | Refreshment Break (Catering areas on 1st and 2nd floor) |
16:00 - 18:00 pm | Concurrent Sessions | |||||
Session A2: Education symposium 'Education pearls in CPT' (Small Hall) Chairs: Michiel van Agtmael, Amsterdam University Medical Center, Amsterdam, the Netherlands and Eriika Savontaus, University of Turku, Turku, Finland | |||||
16:00 - 16:15 | Team-based learning Jitka Rychlíčková, Masaryk University, Brno, Czech Republic | ||||
16:15 - 16:30 | OSCE Ellen van Leeuwen, Ghent University, Ghent, Belgium | ||||
16:30 - 16:45 | Multiprofessional education Karen Keijsers, Jeroen Bosch Hospital, Den Bosch, The Netherlands | ||||
16:45 - 17:00 | Flipped classroom Emilio Sanz, Universidad de La Laguna, La Laguna, Spain | ||||
17:00 - 17:40 | Simulating prescribing in an acute situation Students, Finland (coached by David Brinkman) | ||||
17:40 - 17:45 | Educational virtual escape room Ullamari Pesonen, University of Turku, Turku, Finland | ||||
17:45 - 18:00 | Development of a drug list based on mechanisms of action and INN nomenclature for undergraduate medical training (Abstract O011) Alexander Oksche, Impp, Mainz, Germany | ||||
SSCPT Session B3: Cardiac toxicity (Auditorium) Chairs: Caroline Samer, Hôpitaux Universitaires de Genève, Geneva, Switzerland and Jérôme Bonzon, University Hospital Zurich, Zurich, Switzerland | |||||
16:00 - 16:25 | Clinical aspects of cardiotoxicity in the development of new drugs Martin Bucher, University Hospital Zurich, Zurich, Switzerland | ||||
16:25 - 16:50 | The broad spectrum of drug induced cardiotoxicities Francois Girardin, CHUV, Centre hospitalier universitaire Vaudois, Lausanne, Switzerland | ||||
16:50 - 17:15 | Epigenetic Rewiring in Doxorubicin-Induced Endotheliopathy Shafeeq A. Mohammed, University of Zurich, Zurich, Switzerland | ||||
17:15 - 17:30 | Pharmacogenomics in prediction of cardiovascular drugs’ adverse reaction (PGx-CardioDrug) – data after 4 years (Abstract O012) Livija Šimičević, University of Zagreb School of Medicine, Zagreb, Croatia | ||||
Industry Sponsored Talk by Celerion 17:30 - 18:00 To waive or not to waive; Cardiac liability assessments in early drug development Robert Lester, Celerion, Tempe, Arizona, United States Caroline Engel, Celerion, Montreal, Quebec, Canada | |||||
EPHAR Session C3: RNA therapeutics (Great Hall) Chairs: Maria Jesus Sanz, University of Valencia, Valencia, Spain and Andreas Papapetropoulos, National and Kapodistrian University of Athens, Athens, Greece | |||||
16:00 - 16:30 | RNA therapeutics from theory to practice: an overview of mechanisms and approved drugs Andreas Papapetropoulos, National and Kapodistrian University of Athens, Athens, Greece | ||||
16:30 - 17:00 | Lessons from the development of miR125b*and miR450a for cardioprotection Peter Ferdinandy, Semmelweis University, Budapest, Hungary | ||||
17:00 - 17:30 | We are formulators, how may we help? Lea Ann Dailey, University of Vienna, Vienna, Austria | ||||
17:30 - 17:45 | Towards the fine understanding of local pharmacokinetics adopting integrative multiscale strategy (Abstract O014) Florent Di Meo, Inserm U1248 P&t, Univ. Limoges, Limoges, France | ||||
18:00 - 18:30 | Exhibition Break (Exhibition Hall Agora) | |||||
18:30 - 19:15 | EACPT Lifetime Achievement Award and Lecture (Great Hall) Chair: EACPT Past-Chairman Pierre Marquet, University of Limoges, Limoges, France In this session, we will announce the recipient of the 2025 EACPT Lifetime Achievement Award, followed by a presentation by the awardee. | |||||
19:15 - 20:00 | Opening ceremony (Great Hall) Chair: EACPT2025 Chair Janne Backman, University of Helsinki, Helsinki, Finland
|
20:00 - 21:00 | Reception (Great Hall Foyers) Small snacks available at the reception. 21:00 - 23:00 | Social event at Allas Pool (separate ticket required) |